22 Jan Laverock Therapeutics
David Venables, Ph.D., CEO
April 16 | 5:15pm | Salone dei Cavalieri, Section 2
London, UK
(Private)
Laverock Therapeutics is a gene-silencing company with a uniquely powerful technology which harnesses the cell’s natural gene regulatory mechanisms to develop a new generation of programmable advanced therapies to tackle major diseases. Laverock’s truly innovative technology re-directs naturally-occurring micro RNAs (miRNAs) to conditionally silence genes of choice in a way which is programmable, tunable, stable and specific. This opens a path to more effective, safer and accessible advanced therapies. Laverock’s platform exemplification encompasses ex vivo cell therapy including:
• iPSC derived macrophages engineered to be resistant to the tumour-associated macrophage phenotype and to exclusively polarise to a pro-inflammatory state in the tumour microenvironment.
• CAR-T cells for hard-to-treat cancers where multiple check-point pathways can be conditionally silenced providing improved efficacy without negative affects on effector cell fitness.
• iPSC derived hypoimmune pancreatic islets to treat type 1 diabetes.
